Attenuated methamphetamine induced neurotoxicity by modafinil administration in mice

Methamphetamine (METH) is a highly addictive drug that might induce neurotoxicity. Clinical trials have reported that modafinil, a wake‐promoting agent used to treat sleep disorders, may have some efficacy for the treatment of psychostimulant addiction. In this study we tested possible neuroprotective effects of modafinil after toxic METH administration in mice. We evaluated the effect of modafinil (two injections of either 90 or 180 mg/kg) and METH binge (3 × 7 mg/kg i.p. injections, 3‐h apart) coadministration on DA striatal content, TH immunoreactivity in striatal areas and spontaneous locomotor activity. We also investigated acute locomotor activity and stereotypy profile in mice treated with a single METH dose (2 and 7 mg/kg) pretreated with modafinil (90 and 180 mg/kg). We found that mice treated with a METH binge showed a marked decrease in DA and dopaminergic metabolites as well as lower levels of TH immunoreactivity in the dorsal striatum. Pretreatment with modafinil (both 90 and 180 mg/kg) attenuated these effects but did not prevent METH induced decrease in locomotion. We also found that groups that received the combination of both modafinil and single dose METH showed a decrease in total distance traveled in an open field compared with METH groups. We observed an increment in the time mice expended doing stereotypic movements (continuous sniffing) in the group that received the combination of both METH and modafinil (i.e., decreasing locomotion). Our results suggest a possible protective role of modafinil against METH acute striatal toxicity. Synapse 2011. © 2011 Wiley‐Liss, Inc.

[1]  J. Monterosso,et al.  Effect of Modafinil on Learning and Task-Related Brain Activity in Methamphetamine-Dependent and Healthy Individuals , 2011, Neuropsychopharmacology.

[2]  R. De La Garza,et al.  Modafinil administration improves working memory in methamphetamine-dependent individuals who demonstrate baseline impairment. , 2010, The American journal on addictions.

[3]  R. See,et al.  Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse , 2010, Psychopharmacology.

[4]  D. Ciraulo,et al.  Modafinil for the treatment of cocaine dependence. , 2009, Drug and alcohol dependence.

[5]  V. Setola,et al.  Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil , 2009, Journal of Pharmacology and Experimental Therapeutics.

[6]  N. Volkow,et al.  Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. , 2009, JAMA.

[7]  E. Garcia-Rill,et al.  Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. , 2008, Sleep.

[8]  N. Lambert,et al.  Activity‐dependent regulation of the dopamine transporter is mediated by Ca2+/calmodulin‐dependent protein kinase signaling , 2008, The European journal of neuroscience.

[9]  D. Kuhn,et al.  The newly synthesized pool of dopamine determines the severity of methamphetamine‐induced neurotoxicity , 2008, Journal of neurochemistry.

[10]  S. Vosburg,et al.  Smoked Cocaine Self-Administration is Decreased by Modafinil , 2008, Neuropsychopharmacology.

[11]  R. Vanwersch,et al.  Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy , 2008, Brain Research.

[12]  Meijun Ye,et al.  Electrical coupling: novel mechanism for sleep-wake control. , 2007, Sleep.

[13]  R. Llinás,et al.  Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling , 2007, Proceedings of the National Academy of Sciences.

[14]  G. Hanson,et al.  The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine‐induced dopaminergic deficits , 2007, Journal of neurochemistry.

[15]  C. Berridge Neural Substrates of Psychostimulant-Induced Arousal , 2006, Neuropsychopharmacology.

[16]  H. Sitte,et al.  Calmodulin Kinase II Interacts with the Dopamine Transporter C Terminus to Regulate Amphetamine-Induced Reverse Transport , 2006, Neuron.

[17]  J. Ballon,et al.  A systematic review of modafinil: Potential clinical uses and mechanisms of action. , 2006, The Journal of clinical psychiatry.

[18]  C. Achat-Mendes,et al.  Differential Effects of Amphetamines-Induced Neurotoxicity on Appetitive and Aversive Pavlovian Conditioning in Mice , 2005, Neuropsychopharmacology.

[19]  K. Lynch,et al.  A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence , 2005, Neuropsychopharmacology.

[20]  P. Calabresi,et al.  Abnormal Ca2+-Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism , 2004, The Journal of Neuroscience.

[21]  H. Myrick,et al.  Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues. , 2004, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[22]  V. Luine,et al.  Short toxic methamphetamine schedule impairs object recognition task in male rats , 2002, Brain Research.

[23]  R. Palmiter,et al.  Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Gow,et al.  Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment , 2001, Brain Research Reviews.

[25]  K. Akiyama,et al.  Methamphetamine decreases calcium‐calmodulin dependent protein kinase II activity in discrete rat brain regions , 2000, Synapse.

[26]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[27]  D. Segal,et al.  Repeated binge exposures to amphetamine and methamphetamine: behavioral and neurochemical characterization. , 1997, The Journal of pharmacology and experimental therapeutics.

[28]  R. Ridley,et al.  The psychology of perseverative and stereotyped behaviour , 1994, Progress in Neurobiology.

[29]  C. Vorhees,et al.  The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum , 1994, Brain Research.

[30]  T. Robinson,et al.  Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis , 1986, Brain Research Reviews.

[31]  C. J. Schmidt,et al.  Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid. , 1985, European journal of pharmacology.

[32]  S. Iversen,et al.  Selective 60HDA-induced destruction of mesolimbic dopamine neurons: Abolition of psychostimulant-induced locomotor activity in rats , 1976 .

[33]  S. Iversen,et al.  Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. , 1976, European journal of pharmacology.

[34]  S. Iversen,et al.  Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. , 1973, Brain research.